February 2021

February 25, 2021

From the Co-Chairs, February 2021

COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
February 25, 2021

Now Enrolling: EA3191 for Head and Neck Squamous Cell Carcinoma

This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
February 25, 2021

Institution Spotlight: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

A Standing Main Member of ECOG-ACRIN since 2007
February 25, 2021

News in Brief, February 2021